Open Access

Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review)

  • Authors:
    • Igor Bryukhovetskiy
    • Arina Ponomarenko
    • Irina Lyakhova
    • Sergey Zaitsev
    • Yulia Zayats
    • Maria Korneyko
    • Marina Eliseikina
    • Polina Mischenko
    • Valerie Shevchenko
    • Hari Shanker Sharma
    • Aruna Sharma
    • Yuri Khotimchenko
  • View Affiliations

  • Published online on: May 10, 2018     https://doi.org/10.3892/ijmm.2018.3668
  • Pages: 691-702
  • Copyright: © Bryukhovetskiy et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive brain tumors. GBM represents >50% of primary tumors of the nervous system and ~20% of intracranial neoplasms. Standard treatment involves surgery, radiation and chemotherapy. However, the prognosis of GBM is usually poor, with a median survival of 15 months. Resistance of GBM to treatment can be explained by the presence of cancer stem cells (CSCs) among the GBM cell population. At present, there are no effective therapeutic strategies for the elimination of CSCs. The present review examined the nature of human GBM therapeutic resistance and attempted to systematize and put forward novel approaches for a personalized therapy of GBM that not only destroys tumor tissue, but also regulates cellular signaling and the morphogenetic properties of CSCs. The CSCs are considered to be an informationally accessible living system, and the CSC proteome should be used as a target for therapy directed at suppressing clonal selection mechanisms and CSC generation, destroying CSC hierarchy, and disrupting the interaction of CSCs with their microenvironment and extracellular matrix. These objectives can be achieved through the use of biomedical cellular products.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 42 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bryukhovetskiy I, Ponomarenko A, Lyakhova I, Zaitsev S, Zayats Y, Korneyko M, Eliseikina M, Mischenko P, Shevchenko V, Shanker Sharma H, Shanker Sharma H, et al: Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review). Int J Mol Med 42: 691-702, 2018.
APA
Bryukhovetskiy, I., Ponomarenko, A., Lyakhova, I., Zaitsev, S., Zayats, Y., Korneyko, M. ... Khotimchenko, Y. (2018). Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review). International Journal of Molecular Medicine, 42, 691-702. https://doi.org/10.3892/ijmm.2018.3668
MLA
Bryukhovetskiy, I., Ponomarenko, A., Lyakhova, I., Zaitsev, S., Zayats, Y., Korneyko, M., Eliseikina, M., Mischenko, P., Shevchenko, V., Shanker Sharma, H., Sharma, A., Khotimchenko, Y."Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review)". International Journal of Molecular Medicine 42.2 (2018): 691-702.
Chicago
Bryukhovetskiy, I., Ponomarenko, A., Lyakhova, I., Zaitsev, S., Zayats, Y., Korneyko, M., Eliseikina, M., Mischenko, P., Shevchenko, V., Shanker Sharma, H., Sharma, A., Khotimchenko, Y."Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review)". International Journal of Molecular Medicine 42, no. 2 (2018): 691-702. https://doi.org/10.3892/ijmm.2018.3668